title: The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD).
abstract: The usefulness of ezetimibe was examined in 297 patients with dyslipidemia who did not achieve LDL-C target levels set in JAS 2007 Guidelines by lifestyle modification. The mean period of administration was 178.2±295.4 days. Ezetimibe significantly improved serum lipid levels in the patients with and without non-alcoholic fatty liver disease (NAFLD) (p<0.01). Significant improvement of AST, ALT and γ GTP levels were also observed in the patients with NAFLD (p<0.01, p<0.05, and p<0.01, respectively). Seventy of the patients with NAFLD who underwent abdominal ultrasound before and after administration of ezetimibe were followed. Of those, 38.6% of the patients showed disappearance of steatosis, indicating that administration of ezetimibe is useful in patients with NAFLD.
authors.affiliation: Department of Internal Medicine, Fuji Film Health Care Center. tshiwa@kenpo.fujifilm.co.jp
authors.forename: Tadashi
authors.initials: T
authors.lastname: Shiwa
authors.forename: Yoshiya
authors.initials: Y
authors.lastname: Kawanami
authors.forename: Tomoko
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Akihiko
authors.initials: A
authors.lastname: Moritani
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Hashimoto
authors.forename: Tohru
authors.initials: T
authors.lastname: Gotoh
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use*; D000069438:Ezetimibe; D005234:Fatty Liver / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D014463:Ultrasonography
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D000069438:Ezetimibe